Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 75 Carboplatin 46 Paclitaxel 44 130-nm albumin-bound paclitaxel 35 Gemcitabine 34 Cyclophosphamide 23 Capecitabine 22 Nivolumab 21 Albumin-Bound Paclitaxel 21 atezolizumab 20 sacituzumab govitecan 14 spartalizumab 13 Doxorubicin 11 olaparib 9 Cisplatin 9 Bevacizumab 9 eribulin 8 fludarabine 7 durvalumab 7 avelumab 7 Injections 7 Fulvestrant 7 Fluorouracil 7 Vinorelbine 6 Leucovorin 6 Docetaxel 6 iniparib 5 budigalimab 5 Ipilimumab 5 Epirubicin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Triple Negative Breast Neoplasms × Biopsy, Large-Core Needle × Clear all

NCT05435352 2025-07-30

PEAR-TNBC

Ourotech, Inc.

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡